For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Glucagon
Illustration for Glucagon

THE PEPSRADAR ENCYCLOPEDIA

Glucagon

Release of stored glucose

Prescription medicines · Sources checked 2026-10-04

Read the studies ↓Explore the molecule ↗

Glucagon · KEY FACTS

Content updated · how dates work

Saved peptides

What is Glucagon?

Glucagon is a hormone medicine used to raise dangerously low blood glucose. It serves a different role from medicines aimed at lowering glucose or weight.

Biological role or research focus

Release of stored glucose.

Emergency treatment of severe hypoglycemia is a distinct use from metabolic weight-management research.

Role reference: MedlinePlus · Glucagon ↗

Class / identity
Glucose-raising hormone
Main research area
Severe hypoglycemia rescue
Evidence featured
Human randomized crossover trial
Source check
October 4, 2026

Source: MedlinePlus · Glucagon ↗

Quick answers

Is Glucagon FDA approved?
Yes. Gvoke (NDA 212097), Baqsimi nasal powder (NDA 210134) and glucagon for injection (e.g., NDA 201849) for severe hypoglycemia. Source ↗
Is Glucagon safe?
Approved hormone for severe low blood sugar and as a diagnostic aid; generally well tolerated, but dangerous in people with pheochromocytoma or insulinoma. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
Is Glucagon banned in sport?
It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

1 Human research
StudyTypePopulation / model
Nasal versus intramuscular glucagon (2016)Human randomized crossover trial75 adults with type 1 diabetes under supervised experimental hypoglycemia.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human randomized crossover trial · 2016

Nasal versus intramuscular glucagon

Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.

Population / model
75 adults with type 1 diabetes under supervised experimental hypoglycemia.
Study design
Each participant received the two formulations on separate study visits; glucose recovery was assessed within 30 minutes.
Main finding
Success occurred in 98.7% of nasal visits versus 100% of intramuscular visits. Mean recovery times were 16 and 13 minutes, respectively.
Limits & context
This was a controlled rescue-treatment study, not a comparison of unsupervised use in every emergency. The nasal and injected products have different delivery systems.

Source: Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

15 registered studies name Glucagon as an intervention among the 100 most recently updated of 1541 search results; 8 are recruiting or under way, 3 have not started recruiting yet, 3 completed and 1 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.

StudyStatusPhaseStartPeople
Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy
NCT07642635 · Vanderbilt University Medical Center
RecruitingPhase 1 / Phase 22026-1230
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
NCT07497399 · Johns Hopkins University
RecruitingPhase 22026-04-28120
Semaglutide in Youth With Autism Spectrum Disorder
NCT07770152 · Children's Hospital Medical Center, Cincinnati
RecruitingPhase 42026-10-1842
GLP-1 and Hypoglycemia
NCT01858896 · University of Maryland, Baltimore
CompletedEarly phase 12013-0728
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
NCT07575399 · Amgen
RecruitingPhase 32026-05-11300
Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial
NCT07111494 · Medical College of Wisconsin
RecruitingPhase 42026-05-0122
The Effects of Glucagon on Hepatic Metabolism
NCT05500586 · Adrian Vella
CompletedPhase 1 / Phase 22022-10-2021
Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)
NCT07908316 · Amgen
RecruitingPhase 12026-11-13180

A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 15 listed studies.

Further reading · 4 additional publication links

Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.

Hepatic glucagon action: beyond glucose mobilization. ↗
Physiological reviews · 2024 Jul 1 · Journal Article, Review, Research Support, Non-U.S. Gov't

100 years of glucagon and 100 more. ↗
Diabetologia · 2023 Aug · Journal Article, Review, Research Support, Non-U.S. Gov't
Read available full text ↗

The past, present, and future physiology and pharmacology of glucagon. ↗
Cell metabolism · 2022 Nov 1 · Journal Article, Review, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural
Read available full text ↗

A famsin-glucagon axis mediates glucose homeostasis. ↗
Cell metabolism · 2025 Mar 4 · Journal Article

Repeat this PubMed search ↗
Search additional PubMed records ↗

Risks & interactions

Approved hormone for severe low blood sugar and as a diagnostic aid; generally well tolerated, but dangerous in people with pheochromocytoma or insulinoma.

Human safety data: FDA label

This entry follows the Gvoke VialDx label, which also covers Gvoke. Safety comes from controlled trials in adults and children plus postmarketing reports across glucagon products.

Take extra care with: Heart or blood pressure problemsBlood thinners or bleeding problemsDiabetes or blood-sugar medicines

From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.

Who should not use it

  • People with pheochromocytoma (risk of a sharp rise in blood pressure)
  • People with insulinoma (risk of low blood sugar)
  • Past allergic reaction to glucagon or any ingredient
  • People with glucagonoma, when used as a diagnostic aid

Interactions

  • Beta-blockers: temporary rise in pulse and blood pressure
  • Indomethacin: glucagon may fail to raise blood sugar or may even lower it
  • Warfarin: stronger blood-thinning effect, with more bruising or bleeding
  • Anticholinergic drugs: more gut side effects during diagnostic use
  • Insulin: works against glucagon, so blood sugar needs monitoring

Serious risks

  • Sharp blood pressure rise in undiagnosed pheochromocytoma
  • Low blood sugar in people with insulinoma or glucagonoma
  • Serious allergic reactions, including anaphylactic shock
  • May not work with low liver glycogen stores, such as starvation, adrenal insufficiency or chronic low blood sugar
  • A skin rash (necrolytic migratory erythema) reported with prolonged continuous exposure
  • Higher blood pressure and heart rate in heart disease, and high blood sugar in diabetes, during diagnostic use

Common side effects

  • nausea
  • vomiting
  • injection-site swelling
  • headache
  • low blood sugar (in children)

Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Gvoke VialDx (glucagon) prescribing information ↗

Key precautions

Nausea and vomiting can occur. Pheochromocytoma, insulinoma, and other relevant conditions require product-specific review. A rescue product’s instructions and emergency-care plan matter more than a generic peptide description.

Source: MedlinePlus · Glucagon ↗

Regulatory status

U.S. FDA approval
Approved
Gvoke (NDA 212097), Baqsimi nasal powder (NDA 210134) and glucagon for injection (e.g., NDA 201849) for severe hypoglycemia; also used as a diagnostic aid. Older Lilly and Novo (GlucaGen) applications are listed as discontinued. source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source
World Anti-Doping Agency (2026)
Not on the WADA Prohibited List
Not named and not within a prohibited class on the 2026 List. source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Clinical uses & product context

Approved preparations support emergency treatment of severe hypoglycemia; some injectable products also have diagnostic uses. The linked trial compares nasal and intramuscular rescue formulations.

Source: MedlinePlus · Glucagon ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Why there are no prices here

This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.

Mechanism & research rationale

It prompts the liver to release stored glucose. Certain diagnostic uses also take advantage of its effects on digestive-muscle movement.

Source: MedlinePlus · Glucagon ↗

Molecular structure

Glucagon: 2d molecular structure. The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.⤢ Enlarge 2D
2D molecular structureThe cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.PubChem · CID 16132283 ↗

Questions worth asking

  • Which indication and formulation does the source describe?
  • Does the video make a broader claim than the source supports?
  • Emergency treatment of severe hypoglycemia is a distinct use from metabolic weight-management research.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Video & podcast discussions: members library

Frequently asked questions

Why can glucagon raise glucose while GLP-1 medicines lower it?

They are different hormones with different targets. Similar naming does not imply the same physiological role.

Source: MedlinePlus · Glucagon ↗

Did the nasal study involve real-world unconscious emergencies?

It used supervised insulin-induced hypoglycemia. That controlled setting is an important limitation when interpreting the result.

Source: Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections

MOLECULAR ATLAS

Glucagon

Download illustration ↓Source record ↗
Glucagon 2d molecular structure

The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.